Four of Wall Street's fastest-growing tech companies are converting revenue growth into record cash generation, giving management room to raise profit forecasts.
Nvidia Corp. generated $50.3 billion in operating cash flow last quarter, up 84% from a year earlier, while Micron Technology, CrowdStrike Holdings and Palo Alto Networks each reported similar surges in cash conversion alongside higher profit forecasts.
"The combination of rising cash flow and upward earnings revisions provides stronger confirmation of business momentum than a simple revenue beat," John Vinh, an analyst at KeyBanc Capital Markets, said in a note.
Nvidia's free cash flow reached about $48.6 billion, supporting an additional $80 billion share-repurchase authorization. Consensus fiscal 2027 earnings estimates rose 14% to $9.34 a share from $8.18. Micron's fiscal third-quarter operating cash flow hit $25.39 billion, up from $4.61 billion a year earlier, with free cash flow of $18 billion. CrowdStrike's free cash flow margin widened to 34% from 25%, while Palo Alto's adjusted free cash flow margin expanded 4.3 percentage points to 38.5%.
The cash build provides a buffer against a potential slowdown in AI infrastructure spending, but the stocks' elevated valuations leave little room for error. Nvidia trades at more than 35 times forward earnings, while CrowdStrike changes hands at 138 times — multiples that assume uninterrupted execution.
Cash Conversion Widens the Moat
Nvidia's record operating cash flow gives the chipmaker flexibility to fund product development, secure supply and return capital to shareholders. Vinh maintained his overweight rating on Nvidia with a $330 price target, citing the CUDA software stack's "significant barriers to entry" and the expected Vera Rubin ramp beginning in July. The next-generation architecture, built on TSMC's advanced packaging, is expected to extend Nvidia's lead in AI training and inference workloads.
Micron's cash generation is more cyclical but accelerating faster. Long-term customer agreements provide revenue visibility, though the memory industry's history of overbuilding remains a risk. FactSet expects fiscal 2026 earnings near $73.20 a share, a figure that depends on sustained high-bandwidth memory pricing as HBM3E supply expands.
For cybersecurity companies, the cash story is about platform economics. CrowdStrike's Falcon platform allows customers to add identity, cloud and security modules without the company rebuilding its sales infrastructure for each product. Morgan Stanley analysts said CrowdStrike still had room for valuation expansion, while 22 brokerages raised targets after the quarter. Palo Alto's platformization strategy encourages customers to consolidate network, cloud and AI-security tools with one provider, supporting recurring revenue and cash generation. BTIG called Palo Alto its "top pick," citing stronger momentum and larger contracts.
Valuation Risk Remains the Counterweight
The same cash flows that make these stocks attractive also expose them to compression risk if growth decelerates. CrowdStrike's 138 times forward earnings leaves little protection if annual recurring revenue or cash conversion falls short of elevated expectations. Palo Alto's adjusted cash flow excludes some acquisition-related costs — CyberArk and Chronosphere contributed $388 million of quarterly revenue — making the underlying organic cash generation harder to isolate.
Nvidia faces a different risk: the market may begin discounting the AI buildout before it peaks. ASML's strong equipment orders confirm that manufacturers are expanding capacity, which over time could reduce the scarcity premium on Nvidia's chips. If hyperscalers slow their GPU procurement or begin monetizing existing infrastructure more slowly, Nvidia's cash flow growth could moderate from its current trajectory.
For now, the four companies have delivered what investors want most: cash. The question is whether the market is willing to keep paying a premium for it.
This article is for informational purposes only and does not constitute investment advice.